CompletedPHASE2, PHASE3NCT00137748
Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients
Studying OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Cleveland Clinic
- Principal Investigator
- Jeff T Chapman, MDThe Cleveland Clinic
- Intervention
- CMV-Ig(drug)
- Enrollment
- 50 enrolled
- Eligibility
- All sexes
- Timeline
- 2001 – 2006
Study locations (1)
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00137748 on ClinicalTrials.govOther trials for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05645107A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaGrifols Therapeutics LLC
- RECRUITINGPHASE2, PHASE3NCT05678621Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or ExtensionMonash University
- RECRUITINGNCT00001244Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)National Institute of Allergy and Infectious Diseases (NIAID)
See all trials for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects →